MUC1 antibody
US8883977B2 · kind B2 · utility
6Cited by
1References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 28, 2011 |
| Grant date | Nov 11, 2014 |
| Priority date | — |
| Expiry date | Apr 28, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.